Year
2025
Summary
This research shows that doxorubicin disrupts immune signaling between the spleen and heart, priming inflammatory cells that worsen cardiac damage when hypertension develops later in life. Using a two-hit mouse model, the work reveals a heart–spleen axis and identifies immune cells as targets to protect childhood cancer survivors from heart failure.